Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma.

CPT Pharmacometrics Syst Pharmacol · 2021 · PMC8376139 · PMID 34076364

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a small trendno p-value reported

11 , 12 , 16 In our DREAMM‐2 study (Figure S4 ), there was a small trend for a higher reduction in clearance in responders.

also in 722 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.